AstraZeneca sales of Covid vaccine triple to $1.2bn in first half of 2021

Not-for-profit pledge sees British firm ’s sales revenue fall significantly short of US rival PfizerCoronavirus – latest updatesSee all our coronavirus coverageAstraZeneca ’s Covid-19 vaccine has brought in $1.2bn (£900m) in the first half of this year, with sales tripling in the second quarter from the first – but its earnings remained significantly below those of its US rival Pfizer.Britain ’s biggest drugmaker revealed that it had generated $894m from Covid-19 vaccine sales in the three months to the end of June, following$275m in the first three months of the year. It has pledged to provide the jab, which it developed with Oxford University,on a not-for-profit basis during this pandemic.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: AstraZeneca Vaccines and immunisation Coronavirus Business Pharmaceuticals industry Health Infectious diseases Microbiology World news Pfizer Science Medical research UK news Source Type: news